Hot Features
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial... Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.43 | -14.0609636185 | 10.17 | 10.17 | 8.555 | 2333072 | 8.83922647 | CS |
| 4 | -0.77 | -8.0967402734 | 9.51 | 11.52 | 8.555 | 2312464 | 9.83267524 | CS |
| 12 | 0.08 | 0.923787528868 | 8.66 | 11.52 | 7.535 | 1589488 | 9.31009489 | CS |
| 26 | -3.53 | -28.7693561532 | 12.27 | 12.31 | 7.3575 | 1552598 | 9.24234158 | CS |
| 52 | 1.88 | 27.4052478134 | 6.86 | 12.49 | 5.45 | 1638096 | 8.8459444 | CS |
| 156 | -5.1 | -36.8497109827 | 13.84 | 24.17 | 5.41 | 1286017 | 11.08799638 | CS |
| 260 | -12.97 | -59.7420543528 | 21.71 | 24.17 | 5.41 | 1073454 | 12.19565722 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.